SAN FRANCISCO, December 16, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Vir Biotechnology (VIR). The reason why I want to go over this biotech next is because it is ...

WEST CHESTER, Ohio — Services that help more than 4,000 seniors live more independent lives in Butler County are on the line with voters considering Issue 1 on their November ballot. Issue 1 would ...

September's full moon is approaching, and avid stargazers won't want to miss a chance to see the blood moon. The full moon on Sept. 7 coincides with a total lunar eclipse, meaning the sun, moon and ...

This weekend's full September corn moon of 2025 will also be a very special blood moon, set to rise on Sept. 7 — amid a total lunar eclipse and the rare moment of totality. It will shine for days.

People in the Eastern Hemisphere may see Earth’s shadow pass over the lunar surface, covering our world’s natural satellite in a flush of red. By Katrina Miller Katrina Miller has previously reported ...

ORLANDO, Fla. – It’s a long way away, but it’s never too early to get excited for arguably one of the most breathtaking phenomenon, a total solar eclipse. You may remember all of the buzz of 2024’s ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

(RTTNews) - Northrop Grumman Corp. (NOC), Thursday announced that it has committed $50 million to Firefly Aerospace to accelerate production of their jointly developed medium class launch vehicle, ...

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...